alexa Improvement Of Patients Understanding And Accessibility To Healthcare Services Increase Implementation Of Hepatitis C Virus Therapy In Methadone Maintenance Treatment Patients | 71119
ISSN: 2167-0889

Journal of Liver
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

CO-ORGANIZED EVENT: 5th World Congress on Hepatitis & Liver Diseases & 2nd International Conference on Pancreatic Cancer & Liver Diseases
August 10-12, 2017 London, UK

Rafael Bruck, Einat Peles, Miriam Adelson, Anat Sason, Helena Katchman, Stella Levit, Shaul Schreiber and Oren Shibolet
Tel Aviv University, Israel
Posters & Accepted Abstracts: J Liver
DOI: 10.4172/2167-0889-C1-015
Abstract
Background: Lack of information about the disease and administrative difficulties are major obstacles to hepatitis C virus (HCV) treatment among methadone maintenance treatment (MMT) patients. Methods: HCV seropositive patients treated in the Adelson Clinic rehabilitation center who were abstinent ≥3 months without active psychiatric disorders were invited to a lecture by a Hepatologist on all aspects of HCV disease. During the period of the study, the standard of care for HCV treatment was PEG-RIBA+PI (telaprevir). The participants completed HCV-knowledge and depression questionnaires before and after the lecture and were then referred to evaluation and treatment in the Tel Aviv Medical Center Liver Unit. Results: Of 80 eligible patients, 48 attended the lecture and following the lecture scored significantly better on knowledge about HCV than the non-attendees. Lecture attendance predicted referral to treatment (Odds ratio (OR)=13 (95% confidence interval (CI) I 3.9-44.9 P<0.0005)). Of the 41 referrals, 21(51.2%) actually presented at the Liver Unit, and had lower depression scores (OR=0.2, 95% CI 0.06-0.9 P=0.03). Despite administrative difficulties, 15 participants (71.4%) started evaluation, 12 (80%) initiated interferon-based antiviral treatment and 9 subjects (75%) achieved SVR (1 did not respond to treatment and 2 stopped due to adverse events). Of the 59 who were not present at the Liver Unit, 14 (23.7%) were followed elsewhere but only one of them (7.1%) started treatment. Conclusions: Attendance in a single lecture about HCV, improved knowledge and enhanced HCV treatment initiation among MMT patients, but was adversely affected by depression. In MMT patients, interventions aimed to minimize administrative difficulties and to increase knowledge and awareness to the disease, as well as treatment of depression are necessary. These measures might be even more effective at present, when safe and effective IFN-free therapies to eradicate HCV are widely available.
Biography

Rafael Bruck graduated Medicine in the Sackler Faculty of Medicine at Tel Aviv University, Israel and completed his residency in Internal Medicine in 1986 and his fellowship in Gastrointestinal and Liver Diseases in 1989. During 1989-1991 he did a research fellowship in the Liver Center, Yale University School of Medicine, New Haven, USA. During and after this period Dr. Bruck published several papers about bile physiology in leading journals. Later, upon returning to Israel he continued his basic research and studied prevention of liver damage in various rat models of acute and chronic toxic and immune-mediated liver injury. Dr. Bruck Participated in numerous clinical studies, many as PI, mainly on the treatment of patients with hepatitis C, over 20 years, at first using interferon-based therapies and later with the new DAAs. Dr. Bruck participated in phase II and III clinical trials with many DAAs such as Simeprevir, Daclatasvir and Asunaprevir, Abbvie 3D, Elbasvir and Grazoprevir and Abbvie's new G/P (ENDURNCE 1) compound. Dr. Bruck also participates in clinical studies testing new compounds aimed at the treatment of NASH. Currently, Prof. Bruck is the Deputy of the head of the GI and Liver Institute in Tel Aviv Medical Center in Israel.

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version